Breakfast Technical Briefing on Drug Makers Stocks -- Bristol-Myers Squibb, Johnson & Johnson, Eli Lilly, and Merck

Monday, October 23, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, October 23, 2017 /PRNewswire/ --

If you want a Stock Review on BMY, JNJ, LLY, or MRK then come over to and sign up for your free customized report. The Pharmaceutical industry is the part of the Healthcare sector that deals with medications. Its main goal is to provide drugs that prevent infections, maintain
health, and cure diseases. For today, has issued research reports on four major players in the Drug Manufacturers space: Bristol-Myers Squibb Co. (NYSE: BMY), Johnson & Johnson (NYSE: JNJ), Eli Lilly and Co. (NYSE: LLY), and Merck & Co. Inc. (NYSE: MRK). Daily Stock Tracker published free research reports on these stocks today at:

Bristol-Myers Squibb 

New York headquartered Bristol-Myers Squibb Co.'s stock saw a slight correction of 0.39%, finishing last Friday's trading session at $64.42. A total volume of 5.23 million shares was traded. The Company's shares have gained 1.72% in the last month, 15.86% over the previous three months, and 10.23% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 4.61% and 14.10%, respectively. Additionally, shares of Bristol-Myers Squibb, which discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide, have a Relative Strength Index (RSI) of 57.52.  

On October 16th, 2017, research firm Jefferies downgraded the Company's stock rating from 'Buy' to 'Hold'.

On October 16th, 2017, Bristol-Myers Squibb announced that the US FDA has accepted for priority review its supplemental Biologics License Application for Opdivo (nivolumab) to treat patients with melanoma, who are at high risk of disease recurrence following complete surgical resection. The FDA also previously granted Breakthrough Therapy Designation for this application, which is the seventh indication for which Opdivo has received this designation. See our free and comprehensive research report on BMY at:

Johnson & Johnson 

Shares in New Brunswick, New Jersey-based Johnson & Johnson ended at $142.40, up 0.25% from the last trading session. The stock recorded a trading volume of 5.63 million shares, which was above its three months average volume of 5.37 million shares. The Company's shares have advanced 8.08% in the past month, 7.06% over the previous three months, and 23.60% since the start of this year. The stock is trading 6.82% and 11.85% above its 50-day and 200-day moving averages, respectively. Moreover, shares of the Company have an RSI of 78.07.  

On October 18th, 2017, research firm Stifel reiterated its 'Hold' rating on the Company's stock with an increase of the target price from $140 a share to $142 a share.

On October 19th, 2017, Johnson & Johnson announced that its Board of Directors has declared a cash dividend for Q4 2017 of $0.84 per share on the Company's common stock. The dividend is payable on December 12th, 2017, to shareholders of record at the close of business on November 28th, 2017. The ex-dividend date is November 27th, 2017. JNJ free research report is just a click away at:

Eli Lilly 

On Friday, shares in Indianapolis, Indiana headquartered Eli Lilly and Co. recorded a trading volume of 3.22 million shares. The stock climbed 1.01%, closing the day at $87.23. The Company's shares have gained 4.68% in the last one month, 2.94% over the previous three months, and 18.60% on an YTD basis. The stock is trading 5.39% above its 50-day moving average and 6.81% above its 200-day moving average. Additionally, shares of Eli Lilly have an RSI of 67.83.

On October 16th, 2017, Eli Lilly's Board of Directors has declared a dividend of $0.52per share on outstanding common stock for Q4 2017. The dividend is payable on December 08th, 2017, to shareholders of record at the close of business on November 15th, 2017. Sign up for your complimentary report on LLY at:


At the close of trading on Friday, shares in Kenilworth, New Jersey headquartered Merck & Co. Inc. recorded a trading volume of 10.30 million shares, which was higher than their three months average volume of 7.82 million shares. The stock finished the session 0.20% higher at $63.88. The Company's shares have gained 2.09% in the previous three months and 8.51% since the start of this year. The stock is trading above its 200-day moving average by 0.28%. Furthermore, shares of Merck, which provides healthcare solutions worldwide, have an RSI of 49.25.

On October 12th, 2017, Merck, known as MSD outside of the United States and Canada, announced a collaboration with the American Liver Foundation to raise awareness among US veterans about their increased risk for chronic hepatitis C virus (HCV) infection. Through the initiative, the American Liver Foundation will join events in cities across the U.S. to educate veterans about risk factors for chronic HCV infection, as well as how they can be tested and treated, if appropriate. Register for free on and download the latest research report on MRK at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store